Liver Cancer

Drug delivery technology shows positive results in liver cancer

Published in Cancer Weekly, March 1st, 2005

Delcath Systems, Inc., (NASDAQ:DCTH) announced that U.S. National Cancer Institute researchers, using Delcath technology, achieved encouraging survival and tumor response results in a group of patients with terminal metastatic melanoma in the liver.

The findings, which are preliminary and include the largest subset of patients enrolled in the phase I trial, were reported at the 2005 Gastrointestinal Cancers Symposium held by NCI investigator Jeffrey Farma, MD, a colleague of the study's principal investigator, H. Richard Alexander, MD, head of the NCI's Surgical Metabolism Section.

The expected average survival time for patients diagnosed with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-03-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry